Resources

Noncommunicable diseases (NCDs), including mental health conditions, present a significant challenge to public health and economies globally. The impact of NCDs and mental health conditions is particularly pronounced in the Asia–Pacific region, with a disproportionate burden on low– and middle–income countries.Through a joint effort, PATH and Asian Development Bank aim to drive the adoption of innovative technologies to elevate the management of NCDs and mental health at the primary care level.Together, we launched the ‘Technologies Beyond Borders’ innovations challenge to identify two well–suited innovations for implementation in primary health care settings, to enhance person–centered, high–quality care for NCDs and mental health. These selected technologies will receive support for feasibility assessment and preparation for deployment in primary health care facilities within the targeted Developing Member Countries in the Asian Development Bank portfolio, specifically Bangladesh, Indonesia, Vietnam and Uzbekistan.This compendium is a collection of promising innovations that emerged from the challenge, demonstrating great potential to make a significant impact on public health systems in low– and middle–income countries in the coming years.

Part 2 of "Tools for advancing maternal, newborn and child health (MNCH) advocacy and accountability from subnational to global levels," the second in our Africa regional MNCH advocacy dialogues series, was held on July 3, 2024.It featured a moderated discussion with panelists from PATH, Samasha Medical Foundation, and the Partnership for Maternal, Newborn, and Child Health. The resources below include the presentations delivered by the panelists and recordings of the webinar in both English and French.

This is a simple, Excel-based tool for assessing and comparing financial costs of pneumococcal conjugate vaccine (PCV) vaccination programs with each PCV product available in the global market. It aims to help country-level policymakers specifically in middle-income countries compare products and estimate vaccination program costs for different PCVs, exploring up to four different vaccine options at a time. The tool calculates cold chain volume and costs annually and for a total period of five years. Cost estimates are composed of vaccine cost (i.e., vaccine and supplies procurement and international shipping) and vaccination program costs (i.e., vaccine cost and cost of delivery).It is important to note that cost is only one consideration when selecting a PCV product, and users involved in decision-making around new vaccine introduction/switch or product selection should always consider other dimensions as well. This model is meant to provide insights into the potential costs of alternative product choices and should not replace detailed budget planning once a product has been selected.A user guide is included in the file on a tab labeled “READ ME FIRST” which provides detailed instructions on how to use the tool and interpret the results. The tool is available to download in multiple languages below. Please be sure to check out this six-minute tutorial video, which is in English, with French and Spanish subtitled versions also available. If you have additional questions or need support, contact PATH’s Health Economics & Outcomes Research team: HEOR@path.org.NOTE: Please refer to this web page for the most up-to-date version of the calculator, which is periodically updated to reflect the evolving vaccine landscape.

This is a simple, Excel-based tool for assessing and comparing financial costs of rotavirus vaccination programs with each rotavirus vaccine product available in the global market. It aims to help country-level policymakers specifically in middle-income countries compare products and estimate vaccination program costs for different rotavirus vaccines, exploring up to four different vaccine options at a time. The tool calculates cold chain volume and costs annually and for a total period of five years. Cost estimates are composed of vaccine cost (i.e., vaccine and supplies procurement and international shipping) and vaccination program costs (i.e., vaccine cost and cost of delivery).It is important to note that cost is only one consideration when selecting a rotavirus vaccine product, and users involved in decision-making around new vaccine introduction/switch or product selection should always consider other dimensions as well. This model is meant to provide insights into the potential costs of alternative product choices and should not replace detailed budget planning once a product has been selected.A user guide is included in the file on a tab labeled “READ ME FIRST” which provides detailed instructions on how to use the tool and interpret the results. The tool is available to download in multiple languages. Please be sure to check out this six-minute tutorial video, which is in English, with French and Spanish subtitled versions also available. If you have additional questions or need support, contact PATH’s Health Economics & Outcomes Research team: HEOR@path.org.NOTE: Please refer to this web page for the most up-to-date version of the calculator, which is periodically updated to reflect the evolving vaccine landscape.

The Digital Results Improve Vaccine Equity and Demand (DRIVE Demand) project worked with ministries of health in six countries to strengthen immunization systems and improve equitable vaccine access, uptake, and reach through digital and data tools.Strengthening immunization systems with digital and data toolsWith support from The Rockefeller Foundation, Digital Square at PATH launched the Digital Results Improve Vaccine Equity and Demand (DRIVE Demand) project in June 2022 to aid and inform efforts to increase vaccine demand and acceptance rates in six countries through digitally enabled interventions. The six countries chosen were Honduras, Mali, Tanzania, Thailand, Uganda, and Zambia. The project ended in June 2024.Read the press releaseThe project’s approach leveraged digital and data tools to drive more effective and proactive vaccine interventions in these countries while simultaneously addressing barriers to vaccination such as access, trust, and information sharing. DRIVE Demand is guided by The Rockefeller Foundation's focus on supporting iterative, country-driven, hyper-local efforts to increase demand for vaccination.